Germany's G-BA Confirms That ThromboGenics' JETREA® Demonstrates Significant Therapeutic Benefits for Vitreomacular Traction (VMT) Patients, Including When Associated With Macular Hole

Germany's G-BA Confirms ThatGermany's G-BA Confirms That ThromboGenics' JETREA® Demonstrates Significant Therapeutic Benefits for Vitreomacular Traction (VMT) Patients, Including When Associated With Macular HHoollee PR Newswire LEUVEN, Belgium, October 17, 2013 Decision confirms therapeutic benefits for treatment of VMT patients suffering from mild and moderate symptoms, or 94% of the indicated VMT population ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the Final Early Benefit Assessment from ®the German Federal Joint Committee (G-BA) has concluded that JETREA (ocriplasmin) demonstrates significant added benefit for VMT patients with mild and moderate symptoms when compared with existing comparative treatment (watchful waiting). The mild to moderate VMT population, as referred to by G-BA in its final assessment, represents the vast majority (94%) of the total patient population covered by the approved label. G-BA is the highest decision-making body of the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany. Since the introduction of the early benefit assessment procedure in Germany in January 2011, G-BA has assessed more than sixty innovative ®new drugs. JETREA is to-date one of only six innovative medicines appraised by G-BA to provide significant additional therapeutic benefits for patients.